Ciba Tinosorb sunscreens
This article was originally published in The Rose Sheet
Executive Summary
Ciba Specialty Chemicals should initiate new drug application process for UVA/UVB filters Tinosorb M and Tinosorb S to obtain approval as OTC sunscreens, FDA says in July 15 letter to supplier. Letter denies Ciba's May 21 time and extent application to introduce ingredients in the U.S. based on foreign marketing experience. Ciba has "not demonstrated that the ingredients have been marketed for a material time and a material extent," FDA says, noting under its regulations, ingredients must be marketed for "a minimum of five continuous years in the same country and in sufficient quantity." Ciba sells the ingredients in more than five countries but could only provide two and a half years of continuous use data. TEA was adapted from citizen petition filed by the company Sept. 5, 2000 seeking monograph status for the ingredients (1"The Rose Sheet" Sept. 11, 2000, p. 9). FDA decision is apparently first refusal of TEA for sunscreen ingredients...
You may also be interested in...
Ciba Seeks Addition Of UVA Filters To FDA Sunscreen Monograph
As FDA continues work toward finalizing its sunscreen monograph, Ciba Specialty Chemicals awaits a decision on whether two UVA filters it manufactures will be included in the final rule
Sunscreen Monograph Inclusion Of Two UVA Filters Sought By Ciba
Ciba Specialty Chemicals asks FDA to include two new UVA filter active ingredients in the sunscreen monograph in a citizen petition submitted Sept. 5. The chemicals supplier carries patents for both ingredients.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”